<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(14)</volume><submitter>Wyatt J</submitter><pubmed_abstract>Apoptin is a small viral protein capable of inducing cell death selectively in cancer cells. Despite its potential as an anticancer agent, relatively little is known about its mechanism of toxicity and cancer-selectivity. Previous experiments suggest that cancer-selective phosphorylation modulates apoptin toxicity, although a lack of chemical tools has hampered the dissection of underlying mechanisms. Here, we describe structure-function studies with site-specifically phosphorylated apoptin (apoptin-T108ph) in living cells which revealed that Thr108 phosphorylation is the selectivity switch for apoptin toxicity. Mechanistic investigations link T108ph to actin binding, cytoskeletal disruption and downstream inhibition of anoikis-resistance as well as cancer cell invasion. These results establish apoptin as a protein pro-drug, selectively activated in cancer cells by phosphorylation, which disrupts the cytoskeleton and promotes cell death. We anticipate that this mechanism provides a framework for the design of next generation anticancer proteins with enhanced selectivity and potency.</pubmed_abstract><journal>Chemical science</journal><pagination>3881-3892</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10074440</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Semisynthesis reveals apoptin as a tumour-selective protein prodrug that causes cytoskeletal collapse.</pubmed_title><pmcid>PMC10074440</pmcid><pubmed_authors>Chan YK</pubmed_authors><pubmed_authors>Tavassoli M</pubmed_authors><pubmed_authors>Muller MM</pubmed_authors><pubmed_authors>Hess M</pubmed_authors><pubmed_authors>Wyatt J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Semisynthesis reveals apoptin as a tumour-selective protein prodrug that causes cytoskeletal collapse.</name><description>Apoptin is a small viral protein capable of inducing cell death selectively in cancer cells. Despite its potential as an anticancer agent, relatively little is known about its mechanism of toxicity and cancer-selectivity. Previous experiments suggest that cancer-selective phosphorylation modulates apoptin toxicity, although a lack of chemical tools has hampered the dissection of underlying mechanisms. Here, we describe structure-function studies with site-specifically phosphorylated apoptin (apoptin-T108ph) in living cells which revealed that Thr108 phosphorylation is the selectivity switch for apoptin toxicity. Mechanistic investigations link T108ph to actin binding, cytoskeletal disruption and downstream inhibition of anoikis-resistance as well as cancer cell invasion. These results establish apoptin as a protein pro-drug, selectively activated in cancer cells by phosphorylation, which disrupts the cytoskeleton and promotes cell death. We anticipate that this mechanism provides a framework for the design of next generation anticancer proteins with enhanced selectivity and potency.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-05T12:18:33.534Z</modification><creation>2025-04-05T12:18:33.534Z</creation></dates><accession>S-EPMC10074440</accession><cross_references><pubmed>37035694</pubmed><doi>10.1039/d2sc04481a</doi></cross_references></HashMap>